The Code for Nurses: a nursing practice perspective.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to B Durand.
Explore the source record for details and available documents.
Two commercialized anatoxins, titrating 30 Lf per dose and adsorbed on Ca phosphate and Al hydroxide respectively, were studied in comparison with an experimental anatoxin titrating 25 Lf per dose and adsorbed on Al phosphate, and with a placebo. 595 schoolchildren from Cameroun were randomly assigned to four groups and inoculated twice, with a year's interval between the two inoculations. Serological checks were carried out by double-blind trials using the passive hemagglutination (HA) method on days 7, 90, 365 and 395. HA titers rose substantially after three months and then fell during the 12th month. The HA method does not give a clear indication of the amount of protection obtained after only one inoculation, but this amount would seem to be small according to the results of neutralization tests carried out on samples. It is only after the second injection that protection is provided for most subjects. Results vary depending on the anatoxin and are not linked to the--benign--clinical reactions observed. This study confirms that if anatoxins with high antigenicity are to be used, two injections are necessary and sufficient to guarantee good immunity protection.
Explore the source record for details and available documents.
The conditioned, passive hemagglutination method, which is simple, quick, economical and very sensitive, is suited for large-scale studies in which it is not possible to carry out the in vivo seroneutralization. However, our experience has confirmed that it has certain drawbacks and restrictions: (1) the technique must be applied very carefully and good laboratory training is required. The results obtained by this method vary according to several factors, especially the degree to which the antigen has been purified and its blood carriers, therefore these results are not always consistent; (2) the antibodies found were not a good indication of the degree of protection except at high titers. A study of correlations between HA titers and neutralizing (mice) titers carried out on the basis of 509 double titrations has demonstrated that, whereas they are satisfactory in clearly immune subjects, they show only mediocre results in subjects who are receptive or who are displaying a primary response: a wide range of variation has been observed as well as an optimalization of HA titers, perhaps because of IgM's. Therefore, the HA method, despite its usefulness, cannot provide precise evaluations for: --the amount of protection provided by an anti-tetanus vaccine, --the proportion of protected subjects in a certain group of people, --an injured person's anti-tetanus immunity. We should work to develop in vitro tests which are both sensitive and reliable in terms of the anti-tetanus protection threshold.
Two groups, A and B, were selected at random amongst a total of 31 patients suffering from chronic inflammatory rheumatic disorders. The patients in group A (n = 16) received succesively: Placebo (2d), Indomethacin (5d). Indomethacin + aspirin (5d). The order of the 5 day treatment periods was reversed for the patients in group b (n = 15). The daily dose of indomethacin was 150 mg. That of aspirin was 1500 mg. Four parameters were measured at the end of each period of treatment: total serum indomethacin, articular index (Ritchie), ESR (Westergren) and the sigma ESR - a new technique for the measurement of sedimentation rate. No conclusions could be drawn from the analysis of variations in ESR. Concordant and statistically significnat variations in articular index and the sigma ESR showed a reduction in the activity of indomethacin under the influence of aspirin. The inhibitory effect of aspirin. The inhibitory effect of aspirin continues after the drug stopped. This reduction in indomethacin activity is not related to a decrease in serum concentrations of the medication which are not significantly altered when aspirin is taken.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.